Get the Stockscreener App
2.41
18.31%
-0.54
Milestone Pharmaceuticals Inc stock is traded at $2.41, with a volume of 27.95M.
It is down -18.31% in the last 24 hours and up +24.87% over the past month.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
See More
Previous Close:
$2.95
Open:
$3.05
24h Volume:
27.95M
Relative Volume:
10.71
Market Cap:
$205.26M
Revenue:
-
Net Income/Loss:
$-59.69M
P/E Ratio:
-1.7338
EPS:
-1.39
Net Cash Flow:
$-46.54M
1W Performance:
-10.07%
1M Performance:
+24.87%
6M Performance:
+43.45%
1Y Performance:
+29.57%
1-Day Range:
$1.61
$3.06
1-Week Range:
$1.61
$3.06
52-Week Range:
$0.6254
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Name
Milestone Pharmaceuticals Inc
Sector
Industry
Phone
(514) 336-0444
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
2.41 | 251.25M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-11-25 | Initiated | Wells Fargo | Overweight |
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-20-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-22-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-05-21 | Initiated | H.C. Wainwright | Buy |
| Jul-29-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-24-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-25-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-24-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-04-19 | Initiated | Oppenheimer | Outperform |
| Jun-03-19 | Initiated | Cowen | Outperform |
| Jun-03-19 | Initiated | Jefferies | Buy |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
Milestone Pharmaceuticals Sees Stock Recovery Despite Market Volatility - StocksToTrade
Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025) - ts2.tech
Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded by Wall Street Zen to Sell - MarketBeat
Milestone (NASDAQ: MIST) gains FDA approval for self-use CARDAMYST PSVT spray - Stock Titan
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - GlobeNewswire Inc.
Rocket Lab (RKLB) Stock News Today: Neutron “Hungry Hippo” Milestone, Launch Updates, and Analyst Forecasts (Dec. 12, 2025) - ts2.tech
Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025) - ts2.tech
Milestone Pharmaceuticals Eyes FDA Approval Amid Strong Q3 Results - timothysykes.com
A new trading data show Milestone Pharmaceuticals Inc (MIST) is showing positive returns. - setenews.com
Is Milestone Pharmaceuticals Inc. stock recession proofDip Buying & Long-Term Growth Stock Strategies - Newser
Milestone Pharmaceuticals (Nasdaq: MIST) issues 30,000 options at $2.69 under 2021 Inducement Plan - Stock Titan
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Stock Traders Purchase Large Volume of Call Options on Milestone Pharmaceuticals (NASDAQ:MIST) - MarketBeat
EV Market: Will Milestone Pharmaceuticals Inc. stock gain from lower inflationJuly 2025 Momentum & Advanced Swing Trade Entry Plans - BỘ NỘI VỤ
Milestone Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:MIST) - Defense World
Milestone Pharmaceuticals Inc (MIST) Performance and Fundamentals Dashboard tells a completely different story - Setenews
Will Milestone Pharmaceuticals Inc. stock gain from lower inflation2025 Volatility Report & AI Enhanced Trading Alerts - BỘ NỘI VỤ
Healthy Upside Potential: Milestone Pharmaceuticals Inc (MIST) - setenews.com
Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects - Insider Monkey
Local Pharmaceutical Company Earns $200 Million Milestone Payment in Sarepta Partnership - Pasadena Now
Grasim Industries Limited Trading Near Value Zone Recovery AheadRetail Investor Activity & Low Entry Risk Stocks - earlytimes.in
13 Best Canadian Penny Stocks to Buy Right Now - Insider Monkey
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics - Business Wire
Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Milestone Pharmaceuticals Prepares for CARDAMYST Launch Amid Financial Growth - MSN
Milestone Pharmaceuticals Inc. (MIST) stock price, news, quote and history - Yahoo Finance UK
Milestone Pharmaceuticals Inc. (MIST) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Is Milestone Pharmaceuticals Inc. stock bottoming outJuly 2025 Trade Ideas & Daily Stock Momentum Reports - newser.com
How analysts rate Milestone Pharmaceuticals Inc. stock today2025 Market Trends & Daily Oversold Bounce Ideas - newser.com
Published on: 2025-11-20 02:01:48 - newser.com
Can Milestone Pharmaceuticals Inc. recover in the next quarter2025 Market Sentiment & Free Reliable Trade Execution Plans - newser.com
Published on: 2025-11-19 17:33:54 - newser.com
Why analysts remain bullish on Milestone Pharmaceuticals Inc. stockJuly 2025 PreEarnings & Intraday High Probability Setup Alerts - newser.com
Published on: 2025-11-19 13:39:11 - newser.com
It makes sense and dollars to buy Milestone Pharmaceuticals Inc (MIST) stock - Setenews
Published on: 2025-11-19 06:17:41 - newser.com
Using Bollinger Bands to evaluate Milestone Pharmaceuticals Inc.Weekly Volume Report & AI Powered Market Entry Ideas - newser.com
How Milestone Pharmaceuticals Inc. stock reacts to oil pricesTreasury Yields & Daily Market Momentum Tracking - newser.com
How to forecast Milestone Pharmaceuticals Inc. trends using time series2025 Year in Review & Stock Portfolio Risk Control - newser.com
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Could Be 44% Below Their Intrinsic Value Estimate - Yahoo Finance
What is HC Wainwright's Estimate for MIST FY2025 Earnings? - MarketBeat
What is HC Wainwright’s Estimate for MIST FY2025 Earnings? - Defense World
Will Milestone Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Volume Leaders & Weekly Momentum Picks - newser.com
Can Milestone Pharmaceuticals Inc. stock resist sector downturns2025 Price Momentum & Expert Approved Trade Ideas - newser.com
Milestone Pharmaceuticals Inc Stock (MIST) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):